Janssen Submits Marketing Authorisation Application to the ...
Janssen submitted a Marketing Authorisation Application to the EMA for a single tablet combination therapy of macitentan and tadalafil for PAH treatment, based on Phase 3 A DUE study results showing significant pulmonary haemodynamic improvement. This therapy aims to simplify treatment regimens, potentially improving adherence and outcomes for PAH patients.
Reference News
Janssen Submits Marketing Authorisation Application to the ...
Janssen submitted a Marketing Authorisation Application to the EMA for a single tablet combination therapy of macitentan and tadalafil for PAH treatment, based on Phase 3 A DUE study results showing significant pulmonary haemodynamic improvement. This therapy aims to simplify treatment regimens, potentially improving adherence and outcomes for PAH patients.